Grant of share options

RNS Number : 7264J

Destiny Pharma PLC

23 December 2020

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has granted options ("Options") over 1,985,620 new ordinary shares of £0.01 each in the Company (representing 3.32 per cent. of the Company's issued share capital) to certain employees of the Company, including the Directors and PDMR named below.

Name	Position	Options Issued 2018 LTIP scheme	Options Issued 2020 LTIP scheme	Total Options Held Post Issue
Neil Clark	Chief Executive Officer	205,695	353,692	1,103,692
Shaun Claydon William Love Jesus Gonzalez	Chief Financial Officer Chief Scientific Officer Chief Medical Officer and PDMR	125,000 125,000  115,000	261,538 240,511 219,184	661,538 1,130,905 449,184

The first tranche of Option awards have been made under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. The Options have been granted at a price of 0.01 per Ordinary Share,  will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter. These share option awards were delayed in 2019/20 due to constraints related to the total number of shares in issue.

The second tranche of Options represent awards granted under the new Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options. The Options have been granted with a nominal exercise price and will vest subject to the achievement of Total Shareholder Return measures over a three-year performance period.

Enquiries:

Destiny Pharma plc	[phone]
Neil Clark (Chief Executive Officer) Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker	[phone]
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) Alice Lane (ECM)
WG Partners LLP - Joint Broker	[phone]
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communications	[phone]
Mary Clark / Shabnam Bashir / Manel Mateus

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Ab out Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  https://www.destinypharma.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share  559,387 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	23 December 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 386,538 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	23 December 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bill Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 365,511 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	23 December 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jesus Gonzalez
2.	Reason for the Notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 334,184 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	23 December 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

DSHUORSRRWUUUAA